

BARD1 APPOINTS PROFESSOR ALLAN CRIPPS TO BOARD

- **BARD1 appoints prominent Australian scientist Professor Allan Cripps AO as Non-Executive Director**
- **Professor Cripps provides scientific expertise and diagnostics development experience having led multiple diagnostics projects through clinical validation**
- **This appointment further delivers on our Board renewal process initiated in June 2019**

Perth, Australia, 23 January 2020: BARD1 Life Sciences Limited (ASX:BD1) (**BARD1** or the **Company**), a medical technology company developing non-invasive cancer diagnostics, is pleased to announce the appointment of prominent Australian scientist Professor Allan Cripps as an independent Non-Executive Director, effective 23 January 2020.

BARD1 Chairman, Peter Gunzburg, said: “We are extremely pleased to welcome Allan to BARD1’s Board of Directors. He brings scientific expertise and diagnostics development experience, which combined with his organisational leadership, governance skills and extensive industry networks will be an asset to our Company as we move towards our vision of building a leading Australian cancer diagnostics company.”

Professor Allan Cripps AO, PhD, BSc (Hons), FAHSM, FASM, FAIMS, FIBMS, FCHSM is a distinguished academic, clinical scientist and health services leader, having made significant contributions in immunology, diagnostics and health services delivery. From 2005 to 2016, Professor Cripps was the Pro Vice Chancellor (Health) at Griffith University and is currently a research professor at Griffith University, leading the Mucosal Immunology Research Group within the Menzies Health Institute Queensland. Professor Cripps had near 20 years’ experience in the health and pharmaceutical industries before becoming a full-time academic focusing his research on mucosal immunology, respiratory tract infections, vaccine development and diagnostics. He has published over 300 peer reviewed scientific papers, presented at numerous international scientific conferences, received over \$17 million in Government and industry grant funding and is co-inventor on several international patents in the fields of diagnostics and vaccine protein antigens. He is a fellow of the Australian Academy of Health and Medical Scientists, the Australian Society for Microbiology, the Australian Institute of Medical Scientists, the Institute of Biomedical Scientists (UK) and the Australasian College of Health Service Management. In 2015 he was awarded the Order of Australia (AO) for distinguished service to tertiary education as a senior administrator and to public health as a leading immunologist, academic and researcher in the area of mucosal immunisation.

Currently Professor Cripps is Independent Chair of the Children’s Health Research Alliance Board. He was previously Non-Executive Director of Research Australia (2005 – 2012) and the Gold Coast Hospital and Health Services Board (2011 – 2017).

Professor Cripps said: “I am delighted to join the BARD1 Board and look forward to contributing to the successful commercialisation of the Company’s diagnostic technology and working with management to advance its cancer diagnostics pipeline into diagnostic laboratories to benefit patients through earlier diagnosis.”

BARD1 continues to progress the optimisation phase of our BARD1 autoantibody assay on the Luminex platform with Thermo Fisher Scientific, expansion of our management team, our relocation to Melbourne and our acquisitive growth strategy targeting complimentary assets to expand our diagnostics portfolio.

We look forward to providing further updates on these and other key initiatives to strengthen the business and grow shareholder value during the year.

- ENDS -

COMPANY CONTACTS:**Dr Leearne Hinch**

CEO

E leearne@bard1.com

M +61 400 414 416

Peter Gunzburg

Chairman

E peter@bard1.com**ABOUT BARD1 LIFE SCIENCES LTD**

BARD1 Life Sciences Ltd (ASX:BD1) is an Australian medical technology company focused on developing and commercialising non-invasive diagnostic tests for early detection of cancer. BARD1 owns a proprietary tumour marker platform with potential diagnostic and therapeutic applications across multiple cancers. The pipeline includes BARD1 autoantibody tests in development for early detection of ovarian, breast and lung cancers. BARD1's mission is to detect cancer earlier and save lives. For more information on BARD1, see www.bard1.com.

FORWARD LOOKING STATEMENTS

This announcement contains certain 'forward-looking statements' within the meaning of the securities laws of applicable jurisdictions. Forward-looking statements can generally be identified by the use of forward-looking words such as 'may,' 'should,' 'expect,' 'anticipate,' 'estimate,' 'scheduled' or 'continue' or the negative version of them or comparable terminology. Any forecasts or other forward looking statements contained in this announcement are subject to known and unknown risks and uncertainties and may involve significant elements of subjective judgment and assumptions as to future events which may or may not be correct. There are usually differences between forecast and actual results because events and actual circumstances frequently do not occur as forecast and these differences may be material. The Company does not give any representation, assurance or guarantee that the occurrence of the events expressed or implied in any forward-looking statements in this announcement will actually occur and you are cautioned not to place undue reliance on forward-looking statements.